Pinned Tweet
Truly grateful and proud to be part of a defining moment at #ASH2025.
Contributing as an author to the EPCORE FL-1 trial — with simultaneous publication in @TheLancet and global regulatory impact — was a very special milestone in my academic journey. 🧵👇 – at Orlando, FL
11
12
653
Our new review on AI in lymphoma diagnosis is out.
A realistic look at how AI can support — not replace — clinical practice.
Grateful to Marianne for the invitation and collaboration.
🔗 Link: rdcu.be/eWYH5 – at Brazil
1
103
Abel Costa, MD retweeted
EPCORE FL-1 Trial Shows Promising Results for Follicular Lymphoma - @anetoc
oncodaily.com/voices/abel-co…
#Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag
#ASH2025 was a meaningful milestone in my academic journey.
Being an author on 4 oral presentations and 3 posters highlights the strength of collaborative clinical research and team science.
Grateful to my mentor Eduardo Rego and the IDOR research team. – at Orlando, FL
2
197
One of the moments I was most proud of at #ASH2025 was seeing Luiza Lapolla present data from the Brazilian AML Registry, highlighting how social determinants shape AML outcomes using real-world national data.
@abhhoficial – at Orlando, FL
4
211
Glad to contribute as an author to an oral presentation at #ASH2025 on golca ± rituxi in R/R FL.
High ORR, durable responses, and manageable toxicity, even in heavily pretreated patients, supporting the role of targeted combinations in later lines. – at Orlando, FL
76
Grateful to contribute as an author to the TRAVERSE phase 2 study presented at #ASH2025.
A chemotherapy-free triplet regimen, AVR in treatment-naïve MCL, showed deep responses and high MRD negativity, even in biologically high-risk subgroups. – at Orlando, FL
3
268
For those who want to dive deeper, the full EPCORE FL-1 data are published in The Lancet and have already led to FDA and ANVISA approval.
thelancet.com/journals/lance… – at Orlando, FL
1
45
Taken together, EPCORE FL-1 shows that epcoritamab + R² achieves deep and durable responses, delays the need for subsequent therapy, and maintains a predictable, manageable safety profile, supporting its role as a new standard of care. – at Orlando, FL
1
86
🇧🇷 Proud to represent Brazil in this milestone and to be part of a global study with strong participation from Brazilian centers, contributing to a change in standard of care. – at Orlando, FL
34
Why this matters:
✔️First bispecific antibody approved in combination for FL
✔️Fixed-duration, chemotherapy-free regimen
✔️Immediate impact on treatment sequencing and clinical practice – at Orlando, FL
34
Safety profile was manageable and predictable, with no new safety signals:
• CRS mostly grade 1–2; no grade ≥3 CRS
• No tx discontinuations due to CRS
• Neutropenia and infections were manageable
• >90% relative dose intensity maintained
Compatible with outpatient delivery. – at Orlando, FL
34
Despite still maturing follow-up, EPCORE FL-1 shows a statistically significant early OS signal, with separation of the curves and an HR of 0.38, favoring epcoritamab + R². – at Orlando, FL
78
Beyond PFS, EPCORE FL-1 showed a meaningful improvement in time to next treatment, reinforcing the durability and real-world relevance of responses. – at Orlando, FL
40
Key efficacy results:
• ORR: 95.7% vs 81.0%
• CR: 83% vs 50%
• 79% reduction in risk of progression or death (HR 0.21)
Benefit consistent across prespecified subgroups. – at Orlando, FL
46
EPCORE FL-1 design:
• Phase 3, global, randomized
• Epcoritamab + R² vs R²
• R/R FL after ≥1 prior line
• Dual primary endpoints: ORR and PFS – at Orlando, FL
84
Follicular lymphoma remains a chronic disease for most patients, with diminishing benefit after each line of therapy.
EPCORE FL-1 addressed a critical unmet need: a fixed-duration, chemo-free strategy capable of delivering deep and durable remissions. – at Orlando, FL
2
69
Abel Costa, MD retweeted
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - Annals of Oncology annalsofoncology.org/article…
Abel Costa, MD retweeted
📢We are proud to announce that the EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma are now available online!
Huge thanks to Evangelos Terpos for coordinating such outstanding work! 👉nature.com/articles/s41571-0… @thanosdimop @EHA_Hematology


























